Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Gilles Salles,1 Stephen J. Schuster,2 Sven de Vos,3 Nina D. Wagner-Johnston,4 Andreas Viardot,5 Kristie A. Blum,6 Christopher R. Flowers,7 Wojciech J. Jurczak,8 Ian W. Flinn,9 Brad S. Kahl,10 Peter Martin,11 Yeonhee Kim,12 Sanatan Shreay,12 Matthias Will,13 Bess Sorensen,13 Madlaina Breuleux,13 Pier Luigi Zinzani14 and Ajay K. Gopal15 1Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France; 2Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA; 3Department of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 4Departments of Oncology and Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA; 5Department of Internal Medicine III, University Hospital of Ulm, Germany; 6Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA; 7Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA; 8Department of Hematology, Jagiellonian University, Krakow, Poland; 9Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN, USA; 10Department of Medicine, Oncology Division, Washington University School of Medicine, St Louis, MO, USA; 11Division of Hematology/Oncology, Weill Cornell Medical College, NY, USA; 12Gilead Sciences Inc., Foster City, CA, USA; 13At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA; 14Institute of Hematology and Oncology, University of Bologna, Italy and 15Medical Oncology Division, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA